Citations

Clear

426 citation(s) found for "ST, Reza".

Particulate Matter Pollution Remains a Threat for Cardiovascular Health: Findings From the Global Burden of Disease 2019
Moradi, Mahsa , Behnoush, Amir Hossein , Abbasi‐Kangevari, Mohsen , Moghaddam, Sahar Saeedi , Soleimani, Zahra , Esfahani, Zahra , Naderian, Mohammadreza , Malekpour, Mohammad‐Reza , Rezaei, Nazila , Keykhaei, Mohammad , Khanmohammadi, Shaghayegh , Rezaei, Negar , Farzadfar, Farshad , Kuddus, Mohammed , Saeedi Moghaddam, Sahar , Tavolinejad, Hamed , Rezaei, Negar , Larijani, Bagher , Farzadfar, Farshad , Naderian, Mohammadreza , Rezaei, Nazila , Malekpour, Mohammad-Reza , Larijani, Bagher , Moradi, Mahsa , Khanmohammadi, Shaghayegh , Larijani, Bagher

Mayo Clinic

Journal of the American Heart Association | August 9, 2023 | Volume: 12 | Issue: 16 | Pages: No page available

10.1161/jaha.123.029375 | PMID 37555373 Get It

Background Particulate matter (PM) pollution is a significant risk factor for cardiovascular diseases, causing substantial disease burden and deaths worldwide. This study aimed to investigate the global burden of cardiovascular diseases attributed to PM from 1990 to 2019. Methods and Results We used the GBD (Global Burden of Disease) study 2019 to investigate disability‐adjusted life‐years (DALYs), years of life lost (YLLs), years lived with disability (YLDs), and deaths attributed to PM as well as its subgroups. It was shown that all burden measures' age‐standardized rates for PM were in the same decreasing trend, with the highest decline recorded for deaths (−36.7%). However, the all‐age DALYs increased by 31%, reaching 8.9 million in 2019, to which YLLs contributed the most (8.2 million [95% uncertainty interval, 7.3 million–9.2 million]). Men had higher deaths, DALYs, and YLLs despite lower years lived with disability in 2019 compared with women. There was an 8.1% increase in the age‐standardized rate of DALYs for ambient PM; however, household air pollution from solid fuels decreased by 65.4% in the assessed period. Although higher in men, the low and high sociodemographic index regions had the highest and lowest attributed YLLs/YLDs ratio for PM pollution in 2019, respectively. Conclusions Although the total age‐standardized rate of DALYs for PM‐attributed cardiovascular diseases diminished from 1990 to 2019, the global burden of PM on cardiovascular diseases has increased. The differences between men and women and between regions have clinical and policy implications in global health planning toward more exact funding and resource allocation, in addition to addressing inequity in health care access.
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker
Schmeusser, Benjamin N. , Biermann, Henry, Ali, Adil , Midenberg, Eric, Helman, Talia , Armas‐Phan, Manuel , Nabavizadeh, Reza , Joshi, Shreyas , Bilen, Mehmet Asım , Ogan, Kenneth , Master, Viraj A. , Joshi, Shreyas S, Narayan, Vikram M. , Psutka, Sarah P , Nicaise, Edouard , Patil, Dattatraya , Psutka, Sarah P.

Mayo Clinic

The Oncologist | August 4, 2023 | Volume: 28 | Issue: 12 | Pages: e1219-e1229

10.1093/oncolo/oyad218 | PMID 37540787 Get It

Abstract Introduction Low creatinine to cystatin-C ratio (Cr/Cys-C) may be a biomarker for low-muscle mass. Furthermore, low Cr/Cys-C is associated with decreased overall survival (OS), but to date, has not been examined in patients with renal cell carcinoma (RCC). Our objective is to evaluate associations between low Cr/Cys-C ratio and OS and recurrence-free survival (RFS) in patients with RCC treated with nephrectomy. Methods We performed a retrospective review of patients with RCC treated with nephrectomy. Patients with end-stage renal disease and less than 1-year follow up were excluded. Cr/Cys-C was dichotomized at the median for the cohort (low vs. high). OS and RFS for patients with high versus low Cr/Cys-C were estimated with the Kaplan-Meier method, and associations with the outcomes of interest were modeled using Cox proportional Hazards models. Associations between Cr/Cys-C and skeletal muscle mass were assessed with correlations and logistic regression. Results A total of 255 patients were analyzed, with a median age of 64. Median (IQR) Cr/Cys-C was 1 (0.8-1.2). Low Cr/Cys-C was associated with age, female sex, Eastern Cooperative Oncology Group Performance Status ≥1, TNM stage, and tumor size. Kaplan-Meier and Cox regression analysis demonstrated an association between low Cr/Cys-C and decreased OS (HR = 2.97, 95%CI, 1.12-7.90, P =0.029) and RFS (HR = 3.31, 95%CI, 1.26-8.66, P = .015). Furthermore, a low Cr/Cys-C indicated a 2-3 increase in risk of radiographic sarcopenia. Conclusions Lower Cr/Cys-C is associated with inferior oncologic outcomes in RCC and, pending validation, may have utility as a serum biomarker for the presence of sarcopenia in patients with RCC treated with nephrectomy.
Usability and feasibility of PreventS-MD web app for stroke prevention
Feigin, Valery L. , Krishnamurthi, Rita , Medvedev, Oleg N. , Merkin, Alexander, Nair, Balakrishnan, Jalili-Moghaddam, Shabnam, Barker‐Collo, Suzanne , Ratnasabapathy, Yogini , Skinner, Luke C , Sachdev, Perminder S. , Brainin, Michael , Hankey, Graeme J. , Azarpazhooh, Reza, Bhatia, Anjali , Budinčević, Hrvoje , Child, Nicholas, Chwojnicki, Kamil , Correia, Manuel, Davis, Alan , Devlin, Gerry , Demarin, Vida , Dhamija, Rajinder K. , Ding, Ding , Докова, Клара , Dudley, Makarena , Dyer, Jesse, Edmonds, Misty , Ely, Marcela , Feigin, Svetlana , Fornolles, C, Gall, Seana , Gil, Artyom , George, Ann, Haršány, Michal , Harwood, Matire, Hou, Zeng‐Guang , Ibrahim, Norlinah Mohamed, Ka‘ai, Tania , Kalra, Nidhi , Katzenellenbogen, Judith , Kang, Law Zhe, Kar, Arindam , Kazin, Vitalij, Kamenova, Saltanat , Kondybaeva, A., Lavados, Pablo M, Lee, Tsong‐Hai , Liu, Liping , Mahawish, Karim , Maluchnik, Michał , Martins, Sheila , Mavaddat, Nahal , Mehndiratta, Man Mohan, Oliver, Angela , Öztürk, Şerefnur , Patel, Nikhil, Prakash, B, Roos, Kev, Sekaran, Lakshmanan , Shamalov, N. А. , Solomon, Alina, Suwanwela, Nijasri C., Volevach, Ekaterina , Volný, Ondřej , Wan, Joyce, Withanapathirana, Katila, Welte, Tamara, Wiebers, David O. , Zaidi, Wan Asyraf Wan , Kravchenko, Michael , Barker-Collo, Suzanne , Owolabi, Mayowa , Sachdev, Perminder S , Brainin, Michael , Thrift, Amanda , Hankey, Graeme J , Katzenellenbogen, Judith M , Nair, Balakrishnan, Kravchenko, Michael , Jalili‐Moghaddam, Shabnam , Norrving, Bo , Arroll, Bruce , Thrift, Amanda G. , Abd-Allah, Foad , Akinyemi, Rufus , Bath, Philip M. , Brayne, Carol , Child, Nicholas, Farhoudi, Mehdi , Aziz, Aznida Firzah Abdul , Gabriel, Denis , Gnedovskaya, Elena V. , Harwood, Matire L. N. , Hillis, Argye Elizabeth , Hwang, Kevin O. , Ibrahim, Norlinah Mohamed , Kalra, Nidhi, Karaszewski, Bartosz , Kivipelto, Miia , Lavados, Pablo M. , Mateen, Farrah J. , Mikulík, Robert , Oliver, Angela, Patel, Nikhil, Пирадов, М. А. , Purvis, Tara L. , Reips, Ulf‐Dietrich , Rosand, Jonathan M. , Sahathevan, Ramesh , Silva, Deidre Anne De , Singh, Vinod, Srivastava, M.V. Padma , Taylor, Denise M. , Truelsen, Thomas Clement , Venketasubramanian, Narayanaswamy , Winkler, Andrea Sylvia , Wijeratne, Tissa , Wu, Teddy Y

Mayo Clinic

International Journal of Stroke | July 24, 2023 | Volume: 19 | Issue: 1 | Pages: 94-104

10.1177/17474930231190745 | PMID 37485871 Get It

Background: Most strokes and cardiovascular diseases (CVDs) are potentially preventable if their risk factors are identified and well controlled. Digital platforms, such as the PreventS-MD web app (PreventS-MD) may aid health care professionals (HCPs) in assessing and managing risk factors and promoting lifestyle changes for their patients. Methods: This is a mixed-methods cross-sectional two-phase survey using a largely positivist (quantitative and qualitative) framework. During Phase 1, a prototype of PreventS-MD was tested internationally by 59 of 69 consenting HCPs of different backgrounds, age, sex, working experience, and specialties using hypothetical data. Collected comments/suggestions from the study HCPs in Phase 1 were reviewed and implemented. In Phase 2, a near-final version of PreventS-MD was developed and tested by 58 of 72 consenting HCPs using both hypothetical and real patient (n = 10) data. Qualitative semi-structured interviews with real patients (n = 10) were conducted, and 1 month adherence to the preventive recommendations was assessed by self-reporting. The four System Usability Scale (SUS) groups of scores (0–50 unacceptable; 51–68 poor; 68–80.3 good; >80.3 excellent) were used to determine usability of PreventS-MD. Findings: Ninety-nine HCPs from 27 countries (45% from low- to middle-income countries) participated in the study, and out of them, 10 HCPs were involved in the development of PreventS before the study, and therefore were not involved in the survey. Of the remaining 89 HCPs, 69 consented to the first phase of the survey, and 59 of them completed the first phase of the survey (response rate 86%), and 58 completed the second phase of the survey (response rate 84%). The SUS scores supported good usability of the prototype (mean score = 80.2; 95% CI [77.0–84.0]) and excellent usability of the final version of PreventS-MD (mean score = 81.7; 95% CI [79.1–84.3]) in the field. Scores were not affected by the age, sex, working experience, or specialty of the HCPs. One-month follow-up of the patients confirmed the high level of satisfaction/acceptability of PreventS-MD and (100%) adherence to the recommendations. Interpretation: The PreventS-MD web app has a high level of usability, feasibility, and satisfaction by HCPs and individuals at risk of stroke/CVD. Individuals at risk of stroke/CVD demonstrated a high level of confidence and motivation in following and adhering to preventive recommendations generated by PreventS-MD.
Thrombolysis for central retinal artery occlusion: An individual participant-level meta-analysis
Shahjouei, Shima , Shahripour, Reza Bavarsad , Dumitrascu, Oana M. , Bavarsad Shahripour, Reza , Shahjouei, Shima

Mayo Clinic

International Journal of Stroke | July 10, 2023 | Volume: 19 | Issue: 1 | Pages: 29-39

10.1177/17474930231189352 | PMID 37424312 Get It

Background: Whether thrombolysis improves outcomes in non-arteritic central retinal artery occlusion (naCRAO) is uncertain. We aimed to evaluate the rate of visual recovery after intra-venous thrombolysis (IVT) or intra-arterial thrombolysis (IAT) administration of tissue plasminogen activator (tPA) or urokinase among patients with naCRAO and explore the parameters affecting the final visual acuity (VA). Aim: We systematically searched six databases. Logarithm of the minimum angle of resolution (logMAR) and VA of ⩾20/100 were used to quantify visual recovery. To explore the role of other factors on visual recovery, we defined two models for studies with aggregated data (designs 1 and 2) and 16 models for individual participant data (IPD, models 1–16). Summary of Review: We included data from 771 patients out of 72 publications in nine languages. Visual improvement for ⩾0.3 logMAR was reported in 74.3% of patients who received IVT-tPA within 4.5 h (CI: 60.9–86.0%; unadjusted rate: 73.2%) and 60.0% of those who received IAT-tPA within 24 h (CI: 49.1–70.5%; unadjusted rate: 59.6%). VA of ⩾20/100 was observed among 39.0% of patients after IVT-tPA within 4.5 h and 21.9% of those with IAT-tPA within 24 h. IPD models highlighted the association between improved visual outcomes and VA at presentation, at least 2 weeks follow-up before reporting the final VA, antiplatelet therapy, and shorter symptom onset to thrombolysis window. Conclusion: Early thrombolytic therapy with tPA is associated with enhanced visual recovery in naCRAO. Future studies should refine the optimum time window for thrombolysis in naCRAO.
(40) BLOOD THINNERS: DO THEY NEED TO BE HELD FOR IPP SURGERY?
Niki, Parikh Dr., Reza, Roshandel Dr., Ryan, Griggs Dr., Gerard, H, Paul, Perito Dr., Tobias, Kohler Dr., Paul, Perito Dr.

Mayo Clinic

The Journal of Sexual Medicine | July 7, 2023 | Volume: 20 | Issue: Supplement_4 | Pages: No page available

10.1093/jsxmed/qdad062.009 Get It

Abstract Objectives Inflatable penile prosthesis (IPP) placement on active anticoagulation (AC) is controversial. Techniques utilized to decrease complications include use of malleable implant, partial inflation of IPP for hemostasis, and placement of drain; however risk and benefits must be weighed. We sought to assess outcomes of IPP in men on AC in a multi-institutional study. Methods Data from 3 high-volume implant centers was retrospectively analyzed. Demographics, comorbidities, secondary procedures, drain placement/output, and complications were recorded. Aspirin was excluded as it is not routinely held. Center 1 utilizes a penoscrotal approach without drain placement, center 2 a penoscrotal approach with drain placement (removal when output <50 mL/8 hours), and center 3 an infra-pubic approach with drain for 3 days. Results 202 patients were continued on AC throughout surgery: 112 on clopidogrel, 35 warfarin, 38 apixaban, 1 enoxaparin, 15 rivaroxaban, and 1 combination therapy with clopidogrel and enoxaparin. AC was most continued for peripheral vascular disease (55%), cardiac stents (11.6%), CHF (11%), and atrial fibrillation (11%). Nine patients (3.98%) experienced complications. Four significant events (1 retropubic bleed requiring transfusion, 3 IPP infections) and 5 minor events (3 hematomas, 1 wound dehiscence,1 CT-negative stroke) occurred. Average drain output for center 1 was 223 mL with no hematomas or infections noted. Average drain output for center 2 was 121 mL with most drains removed postoperative day 1. Drain output was significantly higher than historical non-AC controls (p=0.001), however complication rates were not significantly different (p>0.05). AC type, revision surgery, scrotoplasty, or reservoir technique did not affect outcomes or drainage. Conclusions In high-volume implant centers, major complication rate of 1.9% occurred in IPP patients on AC. Although IPP is feasible in this patient population, drain for 3 days and submuscular reservoir placement may be indicated. In most, elective IPP surgery should be delayed until it is safe to discontinue anticoagulation. Conflicts of Interest None
Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases
Farina, Juan M. , Pereyra, Milagros , Mahmoud, Ahmed , Barry, Timothy , Demeter, Susan M. Halli, Ayoub, Chadi , Arsanjani, Reza , Mahmoud, Ahmed K , Barry, Timothy , Halli Demeter, Susan M , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Chao, Chieh‐Ju , Demeter, Susan Halli

Mayo Clinic

Pharmaceuticals | June 26, 2023 | Volume: 16 | Issue: 7 | Pages: 919

10.3390/ph16070919 | PMID 37513831 Get It

Lipoprotein(a) [Lp(a)] is a lipid molecule with atherogenic, inflammatory, thrombotic, and antifibrinolytic effects, whose concentrations are predominantly genetically determined. The association between Lp(a) and cardiovascular diseases (CVDs) has been well-established in numerous studies, and the ability to measure Lp(a) levels is widely available in the community. As such, there has been increasing interest in Lp(a) as a therapeutic target for the prevention of CVD. The impact of the currently available lipid-modifying agents on Lp(a) is modest and heterogeneous, except for the monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), which demonstrated a significant reduction in Lp(a) levels. However, the absolute reduction in Lp(a) to significantly decrease CVD outcomes has not been definitely established, and the magnitude of the effect of PCSK9i seems insufficient to directly reduce the Lp(a)-related CVD risk. Therefore, emerging therapies are being developed that specifically aim to lower Lp(a) levels and the risk of CVD, including RNA interference (RNAi) agents, which have the capacity for temporary and reversible downregulation of gene expression. This review article aims to summarize the effects of Lp(a) on CVD and to evaluate the available evidence on established and emerging therapies targeting Lp(a) levels, focusing on the potential reduction of CVD risk attributable to Lp(a) concentrations.
The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell Carcinoma
Pessoa, Rodrigo Rodrigues , Nabavizadeh, Reza , Quevedo, Fernando , Lohse, Christine M. , Sharma, Vidit , Costello, Brian A. , Boorjian, Stephen A. , Thompson, R. Houston, Leibovich, Bradley C. , Cheville, John C. , Joyce, Daniel

Mayo Clinic

Journal of Urology | June 20, 2023 | Volume: 210 | Issue: 4 | Pages: 611-618

10.1097/ju.0000000000003601 | PMID 37338930 Get It

Anticoagulant therapy in COVID ‐19: A narrative review
Afshar, Zeinab Mohseni , Pirzaman, Ali Tavakoli , Hosseinzadeh, Rezvan , Moghadam, Mohamad Ali Taghizadeh, Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Barary, Mohammad , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Tavakoli Pirzaman, Ali , Babazadeh, Arefeh , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Barary, Mohammad , Ebrahimpour, Soheil

Mayo Clinic

Clinical and Translational Science | June 16, 2023 | Volume: 16 | Issue: 9 | Pages: 1510-1525

10.1111/cts.13569 | PMID 37326220 Get It

Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including coagulopathy and thrombosis. These complications can be the first and sometimes only manifestations of SARS‐CoV‐2 infection and can occur early or late in the course of the disease. However, these symptoms are more prevalent in hospitalized patients with venous thromboembolism, particularly those admitted to intensive care units. Moreover, various forms of arterial and venous thrombosis, or micro‐ or macro‐vasculature embolisms, have been reported during the current pandemic. They have led to harmful consequences, such as neurological and cardiac events, nearly all resulting from the hypercoagulable state caused by this viral infection. The severe hypercoagulability observed in patients with COVID‐19 accounts for most cases of the disease that become critical. Therefore, anticoagulants seem to be one of the most vital therapeutics for treating this potentially life‐threatening condition. In the current paper, we present a thorough review of the pathophysiology of COVID‐19‐induced hypercoagulable state and the use of anticoagulants to treat SARS‐CoV‐2 infections in different patient groups, as well as their pros and cons.
Abstract 14439: Using Augmented Mean Arterial Pressure to Assess Post-Transcatheter Aortic Valve Replacement Mortality
Seri, Amith Reddy , Barry, Timothy , Shanbhag, Anusha , Wang, Yuxiang , Eleid, Mackram F. , Fortuin, F. David , Sweeney, John P., Pollak, Peter , Sabbagh, Abdallah El , Lester, Steven J., Naqvi, Tasneem Z. , Holmes, David R. , Appleton, Chris P, Chao, Chieh‐Ju , Agasthi, Pradyumna , Freeman, William D. , Appleton, Chris P, Arsanjani, Reza

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.14439 Get It

Introduction: Post-transcatheter aortic valve replacement (TAVR) outcome of patients is an important research topic. To accurately assess post-TAVR mortality, we examined a family of new echo-parameters (augmented systolic blood pressure (AugSBP) and arterial mean pressure parameters (AugMAP)) derived from blood pressure and aortic valve gradient ( Figure 1 ). Methods: Patients in the Mayo Clinic National Cardiovascular Diseases Registry-TAVR database who underwent TAVR between January 1, 2012, and June 30, 2017, were identified to retrieve baseline clinical, echocardiographic, and mortality data. The median of AugSBP and AugMAP were used to stratify patients in Kaplan-Meier analysis. Results: The final cohort contained 974 patients with a mean age of 81.4±8.3 years old, and 56.6% were male. The mean Society of Thoracic Surgeons risk score was 8.2±5.2. The median follow-up duration was 354 days, and the one-year all-cause mortality rate was 14.2%. Detailed characteristics are summarized in Table 1. AugMAP1 < 102.5 mmHg (median) was associated with a 3-fold risk of all-cause mortality post-TAVR at 1 year (hazard ratio 3.0, 95%confidence interval 2.0-4.5, p<0.0001)( Figure 1 ). Conclusions: Augmented mean arterial pressure provides clinicians with a simple but effective approach to quickly identify patients at risk and potentially improve post-TAVR prognosis.
Abstract 11187: Impact of Hypertriglyceridemia on Cardiovascular Mortality According to Low-Density Lipoprotein Cholesterol in a 15.6-Million Population
Park, Hyung‐Bok , Arsanjani, Reza , Hong, Sung‐Jin

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.11187 Get It

Introduction: The role of hypertriglyceridemia (HTG) in cardiovascular disease (CVD) remains controversial, especially in persons with well-controlled low-density lipoprotein cholesterol (LDL-C). Hypothesis: We aimed to evaluate the association between triglyceride (TG) levels and CVD mortality according to LDL-C and age in a general population. Methods: From the Korean National Health Insurance Service database, 15,672,028 participants aged 18-99 who underwent routine health examinations were followed up for CVD mortality. Hazard ratios (HRs) for CVD mortality were calculated using Cox models after adjusting for various confounders. Results: During a mean 8.8 years of follow-up, 105,174 individuals died from CVD. There was a clear log-linear association between TG and overall CVD mortality down to 50 mg/dL. Each two-fold increase in TG was associated with 1.10-fold (overall CVD), 1.22-fold (ischemic heart disease [IHD]), 1.24-fold (acute myocardial infarction [AMI]), and 1.10-fold (ischemic stroke) higher CVD mortality. Hemorrhagic stroke and heart failure were not associated with TG levels. The impact of HTG on CVD weakened but remained present in persons with LDL-C <100 mg/dL, in whom each two-fold higher TG was associated with 1.05-fold (overall CVD), 1.12-fold (IHD), 1.15-fold (AMI), and 1.05-fold (ischemic stroke) higher CVD mortality. The younger population (18 to 44 years) had stronger associations between TG levels and mortality from overall CVD, IHD, and AMI than the older population. Conclusions: HTG independently increases CVD mortality. There are residual risks of HTG in both young and older individuals with a low level of LDL-C. HTG management might be beneficial in individuals with well-controlled LDL-C.